Department of Medical and Surgical Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy.
Department of Clinical and Molecular Medicine, University of Rome-Sapienza, Rome, Italy.
Diabetes Metab Res Rev. 2020 Nov;36(8):e3333. doi: 10.1002/dmrr.3333. Epub 2020 May 31.
Non-alcoholic fatty liver disease (NAFLD) is associated with cardiovascular disease (CVD) in patients with type 2 diabetes; nonetheless, it is unknown whether the relationship between NAFLD and CVD occurs also in subjects with prediabetes. Herein, we evaluated whether NAFLD is associated with prevalent CVD in subjects with different glucose tolerance states independently of cardiovascular risk factors.
Presence of NALFD, defined by liver ultrasound, and its association with prevalent composite and individual CVD, including coronary artery disease (CAD) and cerebrovascular disease, was assessed in a cohort of 1254 Caucasian subjects classified as having normal glucose tolerance (NGT, n = 517), prediabetes (n = 397) or type 2 diabetes (n = 340).
Prevalence of NAFLD in the study population was 47.9%. Presence of NAFLD was linked to an augmented prevalence of composite CVD and individual CAD in all the three glucose tolerance groups. In a logistic regression model adjusted for several cardio-metabolic risk factors, subjects with NGT and NAFLD exhibited a 3.2- and 3.4-fold increased risk of having CVD or CAD, respectively, as compared with those without NAFLD. Similarly, subjects with prediabetes and NAFLD showed an increased risk of having CVD or CAD by 2.3- and 2.0-fold, respectively, in comparison to their counterpart without NAFLD. Within the group with type 2 diabetes, subjects having NAFLD displayed a 2.3- and 2.0-fold higher risk of having CVD or CAD, respectively, in comparison to those without NAFLD.
Ultrasonography-defined NAFLD is independently associated with an increased risk of having CVD in individuals with different glucose tolerance.
非酒精性脂肪性肝病(NAFLD)与 2 型糖尿病患者的心血管疾病(CVD)相关;然而,尚不清楚 NAFLD 与 CVD 的关系是否也存在于糖尿病前期患者中。在此,我们评估了不同葡萄糖耐量状态下的 NAFLD 是否与 CVD 的发生率相关,且这种相关性是否独立于心血管危险因素。
通过肝脏超声检查确定 NAFLD 的存在,并评估其与不同葡萄糖耐量状态下的 CVD 复合终点和个体 CVD(包括冠状动脉疾病 [CAD] 和脑血管疾病)的相关性。该队列纳入了 1254 名白种人受试者,分为正常糖耐量(NGT,n = 517)、糖尿病前期(n = 397)和 2 型糖尿病(n = 340)三组。
研究人群中 NAFLD 的患病率为 47.9%。在所有三组葡萄糖耐量人群中,NAFLD 的存在与 CVD 复合终点和 CAD 发生率增加相关。在调整了多种心血管代谢危险因素的逻辑回归模型中,与无 NAFLD 者相比,NGT 且伴有 NAFLD 的受试者发生 CVD 或 CAD 的风险分别增加了 3.2 倍和 3.4 倍。同样,与无 NAFLD 者相比,患有糖尿病前期且伴有 NAFLD 的受试者发生 CVD 或 CAD 的风险分别增加了 2.3 倍和 2.0 倍。在 2 型糖尿病组中,与无 NAFLD 者相比,伴有 NAFLD 的受试者发生 CVD 或 CAD 的风险分别增加了 2.3 倍和 2.0 倍。
超声检查定义的 NAFLD 与不同葡萄糖耐量个体 CVD 风险增加独立相关。